Scop: Nivelul crescut de estrogen are un rol important în carcinogeneza atât a organelor reproductive (ovare, uter, glande mamare
(femei), prostatã (barbaåi)), cât æi în apariåia diferitor tipuri de cancer ale organelor nereproductive, aæa ca plãmânii æi organele
tractului gastrointestinal. Scopul studiului a fost de a analiza riscul de apariåie a cancerului de colon (CC) la pacientele cu cancer al
glandei mamare (CGM) æi hiperestrogenemie.
Material æi metodã: Au fost examinate datele clinico-paraclinice æi anamnestice a 74 de paciente cu CGM æi hiperestrogenemie (lotul
I) æi 58 de paciente cu CGM fãrã hiperestrogenemie (lotul II) în perioada anilor 2014-2019. Analiza a fost efectuatã în baza criteriilor
de screening de la Amsterdam privind riscul de apariåie a CC la pacientele cu CGM.
Rezultate: La 34 din 74 (45,9%) de paciente din lotul I æi 7 din 58 (12,0%) din lotul II a fost înregistratã o istorie familialã agravatã
(rude de gradul I æi II) de patologie a colonului (polipi, CC). De asemenea, 8,1% (6 din 74) æi 3,4% (2 din 58) dintre pacientele cu
CGM din lotul I æi II au prezentat sindroame genetice.
Concluzii: Hiperestrogenemia influenåeazã apariåia CC. Pacientele cu CGM cu hiperestrogenemie, prezintã un risc mai înalt de a
dezvolta CC, comparativ cu pacientele cu CGM fãrã hipestrogenemie.

Purpose: Elevated estrogen levels play an important role in the carcinogenesis of both the reproductive organs (ovaries, uterus,
mammary glands (women), prostate (men)) and in the occurrence of various cancers of non-reproductive organs, such as the lungs
and organs of the gastrointestinal tract. The aim of the study was to analyze the risk of developing colon cancer (CC) for patients
with mammary gland cancer (GCM) and hyperestrogenemia.
Material and methods: The clinical-paraclinical and anamnestic data of 74 patients with CGM and hyperestrogenemia (group I) and
58 patients with CGM without hyperestrogenemia (group II) were examined during the years 2014-2019. The analysis was
performed based on the Amsterdam screening criteria of the risk of developing CC for patients with CGM.
Results: 34 out of 74 (45.9%) patients from group I and 7 out of 58 (12.0%) from group II had an aggravated family history (first
and second degree relatives) of colon pathology (polyps, CC). Also, 8.1% (6 out of 74) and 3.4% (2 out of 58) of patients with CGM
from groups I and II had genetic syndromes.
Conclusions: Hyperestrogenemia influences the appearance of CC. Patients with CGM with hyperestrogenemia have a higher risk of
developing CC compared to patients with CGM without hyperestrogenemia.